Health
STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.
- Published
- (1 h ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 16-word snippet. The full article is at the source.
More from STAT News and around the same time
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discountsMissouri AG told Lilly to stop forcing hospitals to provide claims data to receive discounted medicines under 340B, a sign more states are pushing back against drugmakers.STAT+: FDA offers new details on quicker approval pathway for personalized gene therapiesRare disease advocates applauded the FDA's move to speed access to treatments.STAT+: RFK Jr. goes for broke in IowaKennedy on the campaign trail for MAHA, and new rules loom for U.S. investments in Chinese biotech.STAT+: Nonprofit resurrects shelved gene therapy after startup shuts downLast year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and moreA U.S. judge rejected a bid to block Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugsA possible treatment for brain-eating amoebas, found in the seaBrain-eating amoebas are hard to treat and nearly always fatal. But researchers have isolated a compound that could help stop the disease.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
